Related conditions

Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management. Bridoux F et al. Kidney Int. 2016 Oct 20. pii: S0085-2538(16)30487-2. doi: 10.1016/j.kint.2016.09.004. [Epub ahead of print]. Polyclonal Localized Light Chain Amyloidosis-A Distinct Entity? Ravindran A et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):588-592. doi: 10.1016/j.clml.2016.08.004. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Ravindran A et al. Blood Cancer…

Journal, Library

Emerging treatments

Myeloma CARs are rolling into the clinical arena. Hudecek M et al. Blood. 2016 Sep 29;128(13):1667-8. doi: 10.1182/blood-2016-08-729467. Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. Bilotti E et al. Clin Lymphoma Myeloma Leuk. 2016 Oct;16(10):558-562. doi: 10.1016/j.clml.2016.08.001. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Kumar SK et al. Blood. 2016 Oct 4. pii: blood-2016-05-717769. [Epub ahead of…

Journal, Library

Biology and genetics

Cytogenetics in the management of multiple myeloma: an update by the Groupe francophone de cytogénétique hématologique (GFCH). Daudignon A et al. Ann Biol Clin (Paris). 2016 Oct 1;74(5):588-595. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Sawyer JR et al. Leukemia. 2016 Oct 3. doi: 10.1038/leu.2016.253. [Epub ahead of print]. Knockdown of macrophage inhibitory cytokine-1 in RPMI-8226 human multiple myeloma cells inhibits osteoclastic…

Journal, Library, Management of Myeloma

General

High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges. Muchtar E et al. Leuk Lymphoma. 2016 Oct 13:1-14. [Epub ahead of print]. Is the revised International staging system for myeloma valid in a real world population? Walker I et al. Br J Haematol. 2016 Oct 13. doi: 10.1111/bjh.14341. [Epub ahead of print]. Progress in Myeloma – A Monoclonal Breakthrough. Rajkumar SV et al. N Engl J Med. 2016 Oct 6;375(14):1390-1392. Next-generation multiple…

Journal, Library

Supportive care

A population-based study of the impact of dialysis on mortality in multiple myeloma. Evison F et al. Br J Haematol. 2016 Oct 21. doi: 10.1111/bjh.14394. [Epub ahead of print]. Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study. Yin QS et al. Med Sci Monit. 2016 Oct 20;22:3835-3842. Effect of Systemic Therapies…

Journal, Library, Myeloma Prognosis & Outcomes

Complications of myeloma and its treatments

Management of gynaecologic plasmacytoma: A review article. Feldman AM et al. J Obstet Gynaecol. 2016 Oct 19:1-6. [Epub ahead of print]. Current treatments for renal failure due to multiple myeloma. Gavriatopoulou M et al. Expert Opin Pharmacother. 2016 Nov;17(16):2165-2177. Epub 2016 Sep 27. Comparative Confocal and Histopathological Study of Corneal Changes in Multiple Myeloma. Micali A et al. Cornea. 2016 Oct 5. [Epub ahead of print].…

Journal, Library, Management of complications & side effects

Current treatments

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Mateos MV et al. Ann Hematol. 2016 Oct 14. [Epub ahead of print]. Therapeutic experience of vincristine/cyclophosphamide/melphalan or mitoxantrone/prednisone combination therapy plus thalidomide as first-line induction therapy for…

Journal, Library

Diagnostic tests and prognostic indicators

Utility of flow cytometry studies in the management of patients with multiple myeloma. Paiva B et al. Curr Opin Oncol. 2016 Sep 12. [Epub ahead of print]. Minimal residual disease evaluation in autologous stem cell transplantation recipients with multiple myeloma. Gupta R et al. Leuk Lymphoma. 2016 Sep 23:1-4. [Epub ahead of print]. Role of MRD status in relation to clinical outcomes in…

Diagnosing and Monitoring Myeloma, Journal, Library

Related conditions

Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment. Gertz MA. Am J Hematol. 2016 Sep;91(9):947-56. doi: 10.1002/ajh.24433. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Jelinek T et al. Hematol Oncol. 2016 Sep 20. doi: 10.1002/hon.2351. [Epub ahead of print]. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. Falk RH et…

Journal, Library